- 21 June 2017 New partnership for the treatment of Duchenne muscular disease (DMD)
- 5 April 2017 New step towards the treatment of myotubular myopathy: gene therapy restores strength and prolongs lives in affected dogs
- 30 March 2017 New hope for Duchenne muscular dystrophy
Created in 1990 by AFM-TELETHON, Genethon is fully dedicated to the design and development of gene therapy treatments for rare diseases. Its objective is to provide these innovative treatments to patients affected with rare disorders.
Genethon is developing therapies for rare neuromuscular diseases, immune system or blood disorders, eye disorders and liver diseases.